The reiteration of a Buy rating and maintenance of a $115 price target by Benchmark analyst Bill Sutherland indicates a positive outlook for Amedisys. This news is likely to have a positive short-term impact on the stock price, as it reaffirms the analyst's confidence in the company's performance and potential growth.